Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review

In the present study, we aimed to report our experience with rituximab (RTX) in the treatment of patients with ILD associated with AD (AD-ILD) at a single center. For this purpose, clinical characteristics, radiological findings, and pulmonary function tests (PFTs) of RTX-treated AD-ILD-patients see...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Med
Glavni autori: Atienza-Mateo, Belén, Remuzgo-Martínez, Sara, Prieto-Peña, Diana, Mora Cuesta, Víctor Manuel, Iturbe-Fernández, David, Llorca, Javier, Sánchez-Bilbao, Lara, Corrales, Alfonso, Blanco Rodríguez, Gerardo, Gómez-Román, José Javier, Cifrián, José Manuel, González-Gay, Miguel Ángel
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7598697/
https://ncbi.nlm.nih.gov/pubmed/32977717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9103070
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items